CORAL GABLES, FL / ACCESSWIRE / March 28, 2019 / The healthcare stock market has been a hotbed of excitement in the first few months of 2019 as companies in the industry have focused their efforts on developing innovative technologies and treatments for consumers. The fact of the matter is that without our health, everything else becomes ancillary and unnecessary. Consumers depend and expect healthcare companies to invest in new forms of drug treatments and other aspects of the care experience so that, when a patient needs care, they don't have to look very far. Recently, the healthcare sector has focused on working with artificial intelligence and machine learning to help hospital administrators sort through patient data. Simply put, the future maintenance of humankind rests in the hands of the healthcare sector, and if companies in the space continue to innovate as they have this year, investors looking for lucrative opportunities could benefit from paying close attention. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Arcturus Therapeutics Ltd (ARCT), Sesen Bio Inc (SESN), and Regulus Therapeutics Inc (RGLS) are 4 healthcare companies making moves on Thursday.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care. At a time where consumers depend on healthcare companies to provide quality care solutions, Premier Health is prepared to meet the needs of its patients.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) made headlines yesterday when the Company announced that it has initiated integration of CB2 Insights' medical cannabis Clinical Decision Support tool. Per the details of the initiative, the agreement will give the more than 4600 physicians and healthcare practitioners using Premier Health's Juno EMR platform access to the industry's only medical cannabis-specific CDS tool. CB2 Insights' CDS tool is designed to help incorporate medical cannabis into their patient's treatment plans.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), stated, "we are dedicated to finding new ways to create value for our physician network. We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner."
Arcturus Therapeutics Ltd (ARCT), a leading messenger RNA medicines company focused on the discovery, development, and commercialization of therapeutics towards rare diseases earlier this month reported its financial results for the quarter and year ended December 31, 2018, and provided a corporate update. For the fourth quarter of 2018, Arcturus reported revenue of $7.6 million, compared with $2 million during the fourth quarter of 2017.
In response to the announcement, Joseph Payne, President, and CEO of Arcturus said, "we are excited about the progress Arcturus is making in advancing our portfolio of RNA medicines which we are developing for liver disease, cystic fibrosis, genetic diseases, and vaccine applications. Over the course of 2019, we look forward to reporting on further developments in our pipeline and platform technologies."
Sesen Bio Inc (SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, at the beginning of this month reported new, preliminary analyses from the Company's Phase 3 VISTA trial further demonstrating the activity of Vicinium treatment in patients with high-risk non-muscle invasive bladder cancer.
Dr. Thomas Cannell, President, and CEO of Sesen Bio stated, "we are well underway with our Phase 3 VISTA trial designed to support the full approval of Vicinium for patients with NMIBC. The totality of the efficacy and safety data generated to date in our Phase 3 VISTA trial, and the compelling benefit-risk profile, give us confidence in the approvability of Vicinium for this indication. We believe Vicinium can have a substantial impact on how patients with NMIBC are treated, translating into a significant commercial opportunity, as we endeavor to achieve our mission of saving and renewing the lives of patients with cancer."
Regulus Therapeutics Inc (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, several weeks ago announced the resignation of Dr. Timothy Wright, Chief Research and Development Officer, effective March 15, 2019. Dr. Wright is leaving for personal reasons to pursue a new opportunity and will continue to support Regulus as a scientific advisor.
Immediately following his departure, Jay Hagan, President, and CEO of Regulus commented, "we appreciate Tim's contributions over the last two-plus years at Regulus and are pleased with the strong team he has assembled, capable of advancing the pipeline of innovative microRNA therapeutics. Tim's role as a scientific advisor to the company will enable a smooth transition and support our interactions with FDAregarding RGLS4326."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: